The Hyderabad-based MSN Laboratories, a manufacturer of both formulations and Active Pharmaceutical Ingredients (APIs), is planning to launch four drugs during the current financial year in the domestic market.

According to the company, the products will be in the therapeutic areas such as neurology, cardiology and Central Nervous System (CNS). The company is waiting for the approval from the Drugs Controller General of India (DCGI) to launch the products in the Indian market. It said that all the four drugs would be marketed for the first time in India.

Speaking to the reporters after the launch of Tapal, a novel, centrally acting analgesic for the management of moderate to severe acute pain, Dr M S N Reddy, chairman and managing director, MSN Laboratories, said, “We are looking forward to launch 10 to 12 molecules every year and will cover therapeutic areas such as diabetic, pain management, etc. By launching Tapal, we aim to provide quality product at affordable price to the people.” He added that the cost of the product is one-fifth of its branded version.

The company said that it’s an in-house developed product and is launching for the first time in India. It marked MSN Laboratories’ foray into approximately Rs.3500 crore pain management market. The company, which is marketing the product, may also give it to a few companies for co-marketing in the future.

The company, with focus on the domestic, Asia-Pacific, Latin America and CIS markets, will offer Custom Research And Manufacturing Services (CRAMS) with the completion of its research and development centre in Hyderabad. It is making an investment of Rs.100 crore in the centre. The company is also considering acquisitions in the future when situation arises.